Emilie Aschenbrenner, PharmD, BCOP, on CAR-T Versus Bispecific Antibodies for the Treatment of LBCL

Commentary
Video

The hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin discussed the advantages of each of the 2 modalities in the third and second line settings.

“...CAR-T is still a great option for patients that are fit enough to receive CAR T-cell therapy, are near an authorized treatment center, and have a caregiver. But now with these bispecific antibodies we now have consensus recommendations to give them in the community setting.... They don't necessarily need a dedicated caregiver for that full month, like a CAR T-cell therapy patient.”

Over the past 5 to 6 years, chimeric antigen receptor T-cell (CAR-T) therapy products have carved out an important space as a treatment option for patients with large B-cell lymphoma (LBCL) in the third line and ultimately second line settings. Although, new bispecific antibody treatments may now be poised to overtake this space from CAR-T, at least in some cases. The advantages and disadvantages of each of these 2 treatment modalities were the topic of a debate-style discussion held between Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin, and Katie Gatwood, PharmD, BCOP, a stem cell transplant and cellular therapy clinical pharmacist specialist at Vanderbilt University, at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024. In the debate, Aschenbrenner represented the side of bispecific antibodies and Gatwood represented the side of CAR-T.

CGTLive® sat down with Aschenbrenner shortly after the discussion to learn more. She gave some background context about the debate and spoke about the advantages of each modality, noting that CAR-T has generated unprecedented positive overall survival data in the third line setting and that bispecific antibodies tend to induce fewer and shorter-duration incidences of the toxicities associated with CAR-T, like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). She also touched on areas of interest for future research with these 2 modalities.

Click here for more coverage of Tandem 2024.

REFERENCES
1. Aschenbrenner E. Taking a bite out of CAR-T: Debating use of CAR T-cell therapy vs bispecific antibodies in lymphoma. Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas.

Related Videos
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
© 2024 MJH Life Sciences

All rights reserved.